Role of Yes-associated Protein-1 in Gastrointestinal Cancers and Hepatocellular Carcinoma

Overview

Journal Explor Res Hypothesis Med

Date 2021 Sep 30

PMID 34589656

Citations 1

Authors

Xia Qian

Wei Zhang

Hua Yang

Lanjing Zhang

Ningling Kang

Jinping Lai

Affiliations

Soon will be listed here.

Abstract

Yes-associated protein-1 (YAP1) is a potent transcriptional co-activator and functions as an important downstream effector of the Hippo signaling pathway, which is key to regulating cell proliferation, apoptosis, and organ growth. YAP1 has been implicated as an oncogene for various human cancers including gastrointestinal cancers and hepatocellular carcinoma (HCC). YAP1 promotes tumorigenesis and cancer progression by multiple mechanisms, such as by promoting malignant phenotypes, expanding cancer stem cells, and inducing epithelial-mesenchymal transition. YAP1 overexpression or its activated forms are associated with advanced pathological grades and poor prognosis of cancer, and therefore targeting YAP1 may open a fertile avenue for cancer therapy. In this review, we summarize the recent evidence regarding the role of YAP1 in the carcinogenesis of gastrointestinal cancers and HCC.

Citing Articles

Advances in prognostic and therapeutic targets for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The hippo signaling pathway.

Mranda G, Xiang Z, Liu J, Wei T, Ding Y Front Oncol. 2022; 12:937957.

PMID: 36033517 PMC: 9411807. DOI: 10.3389/fonc.2022.937957.

References

Kim D, Kim S, Lee O, Huang S, Kwon J, Kim J . Differential expression of Yes-associated protein and phosphorylated Yes-associated protein is correlated with expression of Ki-67 and phospho-ERK in colorectal adenocarcinoma. Histol Histopathol. 2013; 28(11):1483-90. DOI: 10.14670/HH-28.1483. View

Wang Y, Xie C, Li Q, Xu K, Wang E . Clinical and prognostic significance of Yes-associated protein in colorectal cancer. Tumour Biol. 2013; 34(4):2169-74. DOI: 10.1007/s13277-013-0751-x. View

Zhao J, Li X, Yang Y, Zhu D, Zhang C, Liu D . Effect of YAP1 silencing on esophageal cancer. Onco Targets Ther. 2016; 9:3137-46. PMC: 4888714. DOI: 10.2147/OTT.S102338. View

Kim G, Kim H, Park Y . Increased expression of Yes-associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular-cholangiocarcinoma. PLoS One. 2013; 8(9):e75449. PMC: 3782432. DOI: 10.1371/journal.pone.0075449. View

Song S, Honjo S, Jin J, Chang S, Scott A, Chen Q . The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clin Cancer Res. 2015; 21(11):2580-90. PMC: 4452384. DOI: 10.1158/1078-0432.CCR-14-2191. View

Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q . Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer. Cell. 2019; 179(5):1239. PMC: 6941747. DOI: 10.1016/j.cell.2019.10.037. View

Pei T, Li Y, Wang J, Wang H, Liang Y, Shi H . YAP is a critical oncogene in human cholangiocarcinoma. Oncotarget. 2015; 6(19):17206-20. PMC: 4627302. DOI: 10.18632/oncotarget.4043. View

Kim W, Khan S, Liu Y, Xu R, Park O, He Y . Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma. Gut. 2017; 67(9):1692-1703. PMC: 6592016. DOI: 10.1136/gutjnl-2017-314061. View

Shibata M, Ham K, Hoque M . A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy. Int J Cancer. 2018; 143(9):2133-2144. PMC: 6540999. DOI: 10.1002/ijc.31561. View

10.

Prieto J, Melero I, Sangro B . Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015; 12(12):681-700. DOI: 10.1038/nrgastro.2015.173. View

11.

Li S, Han Z, Ma Y, Song R, Pei T, Zheng T . Hydroxytyrosol inhibits cholangiocarcinoma tumor growth: an in vivo and in vitro study. Oncol Rep. 2013; 31(1):145-52. DOI: 10.3892/or.2013.2853. View

12.

Han S, Bai E, Jin G, He C, Guo X, Wang L . Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J Immunol Res. 2014; 2014:261365. PMC: 4016924. DOI: 10.1155/2014/261365. View

13.

Tschaharganeh D, Chen X, Latzko P, Malz M, Gaida M, Felix K . Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology. 2013; 144(7):1530-1542.e12. PMC: 3665638. DOI: 10.1053/j.gastro.2013.02.009. View

14.

Song S, Li Y, Xu Y, Ma L, Pizzi M, Jin J . Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma. Mol Oncol. 2020; 14(6):1410-1426. PMC: 7266288. DOI: 10.1002/1878-0261.12667. View

15.

Miao J, Hsu P, Yang Y, Xu Z, Dai Y, Wang Y . YAP regulates PD-L1 expression in human NSCLC cells. Oncotarget. 2018; 8(70):114576-114587. PMC: 5777715. DOI: 10.18632/oncotarget.23051. View

16.

Jeong S, Kim H, Kim M, Lee J, Lee J, Kim J . Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer. J Clin Invest. 2018; 128(3):1010-1025. PMC: 5824861. DOI: 10.1172/JCI95802. View

17.

Zhou D, Zhang Y, Wu H, Barry E, Yin Y, Lawrence E . Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci U S A. 2011; 108(49):E1312-20. PMC: 3241824. DOI: 10.1073/pnas.1110428108. View

18.

Pobbati A, Hong W . Emerging roles of TEAD transcription factors and its coactivators in cancers. Cancer Biol Ther. 2013; 14(5):390-8. PMC: 3672182. DOI: 10.4161/cbt.23788. View

19.

Guo X, Zhao Y, Yan H, Yang Y, Shen S, Dai X . Single tumor-initiating cells evade immune clearance by recruiting type II macrophages. Genes Dev. 2017; 31(3):247-259. PMC: 5358722. DOI: 10.1101/gad.294348.116. View

20.

Lee K, Lee S, Kim S, Sohn B, Lee H, Jang H . Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. Clin Cancer Res. 2014; 21(2):357-64. PMC: 4513664. DOI: 10.1158/1078-0432.CCR-14-1374. View